PLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS
Cardiovascular diseases are the main cause of death in the world. Next to efforts to reduce the cardiovascular risk factors, several drugs are resorted to decrease morbimortality associated to these diseases: antihypertensive, antidiabetic, hypolipemiant and platelet antiaggregant drugs are used amo...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Universidad de Antioquia
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/31500303069f477ca93935deba6ecb97 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Cardiovascular diseases are the main cause of death in the world. Next to efforts to reduce the
cardiovascular risk factors, several drugs are resorted to decrease morbimortality associated to these
diseases: antihypertensive, antidiabetic, hypolipemiant and platelet antiaggregant drugs are used among
others.
Due to the participation of platelets, not only in the early stages of the atherogenesis but also in the
artery thromboses, the use of platelet antiaggregant drugs is very relevant in the primary and secondary
prevention of the artery thrombosis.
In this review, after a brief description of the primary hemostasis, aspects of antiplatelet like mechanisms
of action and use asocied risks during the last 10 years are adressed. Primarily literature source was www.pubmed.com. The terms used in the search were: platelet antiaggregant, aspirin, dipyridamole,
clopidogrel, abciximab, among others, then we searched the full texts of articles of interest and also used
some hematology books.
|
|---|